share_log

Moderna | 8-K: Current report

Moderna | 8-K: Current report

Moderna | 8-K：重大事件
美股SEC公告 ·  09/12 18:09
牛牛AI助理已提取核心訊息
On September 12, 2024, Moderna, Inc. provided updates on its research and development progress and strategic priorities during its annual R&D Day event. The company announced positive Phase 3 results for several vaccines, including its RSV vaccine for high-risk adults and its standalone flu vaccine for older adults. Moderna also revealed plans to submit its next-generation COVID vaccine and a flu/COVID combination vaccine for approval in 2024. Additionally, the norovirus vaccine has advanced into Phase 3 study. To optimize its R&D expenditure, Moderna is implementing cost efficiencies to reduce R&D expenses by $1.1 billion by 2027. The company's financial framework has been updated through 2028, with a focus on 10 product approvals by 2027. Moderna's CEO, Stéphane Bancel, emphasized the company...Show More
On September 12, 2024, Moderna, Inc. provided updates on its research and development progress and strategic priorities during its annual R&D Day event. The company announced positive Phase 3 results for several vaccines, including its RSV vaccine for high-risk adults and its standalone flu vaccine for older adults. Moderna also revealed plans to submit its next-generation COVID vaccine and a flu/COVID combination vaccine for approval in 2024. Additionally, the norovirus vaccine has advanced into Phase 3 study. To optimize its R&D expenditure, Moderna is implementing cost efficiencies to reduce R&D expenses by $1.1 billion by 2027. The company's financial framework has been updated through 2028, with a focus on 10 product approvals by 2027. Moderna's CEO, Stéphane Bancel, emphasized the company's high success rate in R&D and the need to concentrate on delivering these products to patients while slowing the pace of new R&D investments. The company also announced discontinuation of five programs in its pipeline as part of its strategic prioritization. Moderna expects its commercial respiratory franchise to be profitable in 2024 and projects a revenue of $2.5 billion to $3.5 billion in 2025, with a compounded annual growth rate of over 25% for 2026-2028.
2024年9月12日，Moderna公司在其年度研發日活動期間提供了其研究和開發進展以及戰略重點的更新。該公司宣佈了幾種疫苗的第三階段的積極結果，包括其用於高風險成人的RSV疫苗和用於老年人的單獨流感疫苗。Moderna還透露計劃在2024年提交其下一代COVID疫苗和流感/COVID聯合疫苗的批准申請。此外，諾如病毒疫苗已進入第三階段研究。爲了優化研發支出，Moderna正在實施成本效益措施，以到2027年將研發費用降低11億美元。公司的財務框架已經更新至2028年，並專注於在2027年之前獲得10個產品的批准。Moderna的CEO Stéphane Bancel強調了公司在研發方面的高成...展開全部
2024年9月12日，Moderna公司在其年度研發日活動期間提供了其研究和開發進展以及戰略重點的更新。該公司宣佈了幾種疫苗的第三階段的積極結果，包括其用於高風險成人的RSV疫苗和用於老年人的單獨流感疫苗。Moderna還透露計劃在2024年提交其下一代COVID疫苗和流感/COVID聯合疫苗的批准申請。此外，諾如病毒疫苗已進入第三階段研究。爲了優化研發支出，Moderna正在實施成本效益措施，以到2027年將研發費用降低11億美元。公司的財務框架已經更新至2028年，並專注於在2027年之前獲得10個產品的批准。Moderna的CEO Stéphane Bancel強調了公司在研發方面的高成功率以及需要集中精力將這些產品交付給患者，同時減緩新研發投資的速度。公司還宣佈在戰略優先次序中取消了五個項目。Moderna預計其商業呼吸道產品組合將在2024年實現盈利，並預測2025年的營業收入爲25億至35億美元，2026年至2028年的年複合增長率超過25%。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。